Sanofi India Limited (SANOFI)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 21 July 2026

₹3,383.3 ↓ 42.79% (1Y)

🎯 Key Takeaways

Sanofi India is navigating a strategic transition phase marked by leadership succession, portfolio realignment in diabetes, and stabilization in export markets after a period of volatility. The company is repositioning its governance and commercial structure while managing margin pressures from shifting partnership dynamics and therapeutic focus.
Revenue declined 1.7% QoQ to ₹515 in Q3FY25.
⚠️ Margin pressure persists despite revenue recovery, linked to strategic shifts in partnerships and potential pricing or cost-of-goods impacts.

Market Cap

₹7,411

P/E Ratio

17.9

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About SANOFI 📊 Interactive Charts

📖 The Story

Sanofi India is navigating a strategic transition phase marked by leadership succession, portfolio realignment in diabetes, and stabilization in export markets after a period of volatility. The company is repositioning its governance and commercial structure while managing margin pressures from shifting partnership dynamics and therapeutic focus.

📰 What's Happening

In Q1 FY26 (March 2026), revenue rose to ₹4,767 million from ₹4,226 million in Q4 FY25, driven by double-digit growth in the insulin portfolio and stabilizing export sales, though net profit declined to ₹1,026 million from ₹1,195 million in the same quarter last year. The Board appointed Rahul Bhatnagar as Chairman effective April 30, 2026, succeeding Aditya Narayan, while retaining key independent directors. Debajit Roy was appointed Head of Sales & Customer Engagement for Diabetes on June 8, 2026, signaling a focused push on diabetes growth. The company also completed re-constitution of key committees and reappointed directors following its AGM on April 29, 2026, with Haresh Vala retiring after leading during a period of partnership transitions.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	706	715	694	732	464	524	515
Operating Profit	194	220	199	199	102	122	132
OPM %	25.2%	29.1%	27.0%	29.9%	25.0%	22.8%	23.0%
Net Profit	123	152	138	137	103	82	91
EPS	₹53.37	₹65.95	₹59.79	₹59.31	₹44.81	₹35.69	₹39.64

Revenue trends show a recovery pattern after a peak in Q4 FY24 (₹732 million), with sequential growth in Q1 FY25 and Q4 FY25, but a year-on-year decline in net profit from ₹1,195 million to ₹1,026 million in Q1 FY26. Operating margins have moderated from over 29% in late FY24 to 21.5% in Q1 FY26, reflecting pricing pressures or cost structure changes linked to partnership shifts. Despite this, gross profitability remains intact, with operating profit holding at ₹1,026 million in Q1 FY26, suggesting improved cost control offsetting revenue headwinds.

🔮 Management Outlook & What's Next

Management has not provided forward guidance in the latest filings, but past communications indicate continued focus on diabetes therapy growth, export market stabilization, and operational efficiency. The appointment of Bhatnagar as Chairman and Roy to lead diabetes commercialization suggests an intent to strengthen strategic execution. No explicit revenue or margin targets were disclosed in the recent results or board updates.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Margin pressure persists despite revenue recovery, linked to strategic shifts in partnerships and potential pricing or cost-of-goods impacts. 2. Net profit declined YoY in Q1 FY26 despite higher revenue, signaling vulnerability in profitability under current therapeutic or commercial models. 3. Leadership transitions in key roles (Chairman, diabetes commercial head) may introduce execution risks during the stabilization phase. 4. Export sales stabilization is critical but unconfirmed in forward-looking statements, making revenue sustainability uncertain.

📋 Recent Filings

🧠 Analyst's Read

Sanofi India is in a transitional phase with emerging leadership and strategic focus on diabetes, but profitability is under strain amid revenue volatility. Investors should monitor export trends, margin recovery, and the commercial impact of new appointments in the coming quarters.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on SANOFI

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-21.

📡 Get AI alerts when SANOFI files new disclosures

Track SANOFI filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SANOFI — Free

Free account · 2 AI queries/day